Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ACTRN12626000311358) titled 'An ALLG international randomised phase III trial of Surovatamig versus radiotherapy with or without Rituximab in limited stage nodal Follicular Lymphoma' on March 11.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Primary Sponsor: Australasian Leukaemia and Lymphoma Group
Condition:
Follicular Lymphoma
Follicular Lymphoma
Cancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Intervention:
The intervention is Surovatamig. Surovatamig is supplied as a concentrate for solution for intravenous administration (2mg/mL).
Arm A (Investigational ...